Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Biobizkaia (18)

2023

  1. Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment

    International Review of Neurobiology (Academic Press Inc.), pp. 103-143

  2. Review of Technological Challenges in Personalised Medicine and Early Diagnosis of Neurodegenerative Disorders

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

  3. Sexual differences in locus coeruleus neurons and related behavior in C57BL/6J mice

    Biology of Sex Differences, Vol. 14, Núm. 1

  4. Targeting parvalbumin-expressing neurons in the substantia nigra pars reticulata restores motor function in parkinsonian mice

    Cell Reports, Vol. 42, Núm. 10

2022

  1. Identification of potentially irritating intravenous medications

    Enfermeria Intensiva, Vol. 33, Núm. 3, pp. 132-140

  2. Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation

    Frontiers in Pharmacology, Vol. 13

2021

  1. Study of tissue-specific reactive oxygen species formation by cell membrane microarrays for the characterization of bioactive compounds

    Membranes, Vol. 11, Núm. 12

  2. The effect of 5-HT1A receptor agonists on the entopeduncular nucleus is modified in 6-hydroxydopamine-lesioned rats

    British Journal of Pharmacology, Vol. 178, Núm. 12, pp. 2516-2532

  3. Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations

    Molecular Therapy - Nucleic Acids, Vol. 25, pp. 585-602

2020

  1. 6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata

    British Journal of Pharmacology, Vol. 177, Núm. 17, pp. 3957-3974

  2. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers

    Frontiers in Neuroscience, Vol. 14

  3. Current Techniques for Investigating the Brain Extracellular Space

    Frontiers in Neuroscience, Vol. 14

  4. Editorial: Non-Dopaminergic Systems in Parkinson’s Disease

    Frontiers in Pharmacology

  5. The Noradrenergic System in Parkinson’s Disease

    Frontiers in Pharmacology, Vol. 11

2019

  1. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats

    Experimental Neurology, Vol. 322

  2. Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia

    International Review of Neurobiology (Academic Press Inc.), pp. 259-279

  3. Effects of adult enriched environment on cognition, hippocampal-prefrontal plasticity and NMDAR subunit expression in MK-801-induced schizophrenia model

    European Neuropsychopharmacology, Vol. 29, Núm. 5, pp. 590-600

2016

  1. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson's disease

    Journal of Biomedical Nanotechnology, Vol. 12, Núm. 12, pp. 2220-2230